| Companies sponsors |
Merck Group |
| |
Department of Health and Social Care |
| |
Health Technology Wales |
| |
NHS England |
| Patient carer groups |
Multiple Sclerosis Trust |
| |
Multiple Sclerosis Society |
| Professional groups |
Association of British Neurologists |
| |
Royal College of Physicians |
| Associated public health groups |
Public Health Wales |
| |
UK Health Security Agency |
| Comparator companies |
Almirall (dimethyl fumarate) (not participating) |
| |
Axunio Pharma (teriflunomide) (not participating) |
| |
Bayer (interferon beta 1-b) (not participating) |
| |
Biogen Idec (dimethyl fumarate, interferon beta-1a, peginterferon beta-1a, diroximel fumarate) |
| |
Celix Pharma (dimethyl fumarate) (not participating) |
| |
Dr. Reddy’s Laboratories (teriflunomide) (not participating) |
| |
Johnson & Johnson Innovative Medicine (ponesimod) |
| |
Merck (interferon beta-1a) (not participating) |
| |
Mylan (dimethyl fumarate, glatiramer acetate, teriflunomide) (not participating) |
| |
Novartis (interferon beta-1b, ofatumumab, siponimod) |
| |
Roche (ocrelizumab) (not participating) |
| |
Sandoz (teriflunomide) |
| |
Sanofi Genzyme (teriflunomide) |
| |
Teva UK (glatiramer acetate) (not participating) |
| |
Zentiva (dimethyl fumarate) (not participating) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |